Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
Cadrenal Therapeutics (CVKD) has appointed James J. Ferguson, MD, FACC, FAHA as its new Chief Medical Officer, replacing Douglas W. Losordo, MD. Dr. Ferguson, with over 25 years of cardiovascular leadership experience, will lead the late-stage clinical development of tecarfarin, a new Vitamin K antagonist, focusing on pivotal trials in LVAD patients and other rare cardiovascular conditions requiring life-long anticoagulation therapy.
Dr. Ferguson joins from Matinas BioPharma, where he served as Chief Medical Officer. His previous roles include Head of U.S. Cardiovascular Medical Affairs at Amgen and various senior positions at AstraZeneca. The appointment aims to advance tecarfarin's development as the first innovation in vitamin K-targeted anticoagulation in 70 years.
Cadrenal Therapeutics (CVKD) ha nominato James J. Ferguson, MD, FACC, FAHA come suo nuovo Direttore Medico, sostituendo Douglas W. Losordo, MD. Il Dr. Ferguson, con oltre 25 anni di esperienza nella leadership cardiovascolare, guiderà lo sviluppo clinico in fase avanzata di tecarfarin, un nuovo antagonista della vitamina K, concentrandosi su trial fondamentali in pazienti con LVAD e altre rare condizioni cardiovascolari che richiedono terapia anticoagulante a lungo termine.
Il Dr. Ferguson proviene da Matinas BioPharma, dove ha ricoperto il ruolo di Direttore Medico. Le sue precedenti cariche includono Responsabile degli Affari Medici Cardiovascolari negli Stati Uniti presso Amgen e vari ruoli di alto livello in AstraZeneca. La nomina mira ad avanzare lo sviluppo di tecarfarin come la prima innovazione nell'anticoagulazione mirata alla vitamina K negli ultimi 70 anni.
Cadrenal Therapeutics (CVKD) ha nombrado a James J. Ferguson, MD, FACC, FAHA como su nuevo Director Médico, reemplazando a Douglas W. Losordo, MD. El Dr. Ferguson, con más de 25 años de experiencia en liderazgo cardiovascular, liderará el desarrollo clínico en etapas avanzadas de tecarfarin, un nuevo antagonista de la vitamina K, centrando su atención en ensayos cruciales en pacientes con LVAD y otras raras condiciones cardiovasculares que requieren terapia anticoagulante de por vida.
El Dr. Ferguson se une desde Matinas BioPharma, donde se desempeñó como Director Médico. Sus roles anteriores incluyen Jefe de Asuntos Médicos Cardiovasculares en EE. UU. en Amgen y varios cargos senior en AstraZeneca. El nombramiento tiene como objetivo avanzar en el desarrollo de tecarfarin como la primera innovación en anticoagulación dirigida a la vitamina K en 70 años.
Cadrenal Therapeutics (CVKD)는 James J. Ferguson, MD, FACC, FAHA를 새 최고 의학 책임자로 임명하며 Douglas W. Losordo, MD를 대체했습니다. Ferguson 박사는 25년 이상의 심혈관 리더십 경험을 가진 인물로, LVAD 환자 및 평생 항응고 치료가 필요한 기타 드문 심혈관 질환을 대상으로 테카르파린의 후기 임상 개발을 이끌게 됩니다.
Ferguson 박사는 Matinas BioPharma에서 최고 의학 책임자로 재직한 이력을 가지고 있으며, 이전에는 Amgen에서 미국 심혈관 의학 업무 책임자로 활동했고 AstraZeneca에서 여러 고위직을 역임했습니다. 이번 임명의 목적은 지난 70년간 비타민 K에 타겟을 둔 항응고제의 첫 번째 혁신으로서 테카르파린 개발을 추진하는 것입니다.
Cadrenal Therapeutics (CVKD) a nommé James J. Ferguson, MD, FACC, FAHA comme son nouveau Directeur Médical, remplaçant Douglas W. Losordo, MD. Le Dr. Ferguson, avec plus de 25 ans d'expérience en leadership cardiovasculaire, dirigera le développement clinique avancé de tecarfarin, un nouvel antagoniste de la vitamine K, en se concentrant sur des essais décisifs chez les patients LVAD et d'autres conditions cardiovasculaires rares nécessitant une thérapie anticoagulante à vie.
Le Dr. Ferguson rejoint Matinas BioPharma, où il a exercé la fonction de Directeur Médical. Ses précédents postes incluent Responsable des Affaires Médicales Cardiovasculaires aux États-Unis chez Amgen et divers postes de direction chez AstraZeneca. Cette nomination vise à faire progresser le développement de tecarfarin en tant que première innovation dans l'anticoagulation ciblant la vitamine K en 70 ans.
Cadrenal Therapeutics (CVKD) hat James J. Ferguson, MD, FACC, FAHA als neuen Chief Medical Officer ernannt, der Douglas W. Losordo, MD ersetzt. Dr. Ferguson verfügt über mehr als 25 Jahre Erfahrung in der kardiovaskulären Führung und wird die klinische Entwicklung in der späten Phase von tecarfarin, einem neuen Vitamin-K-Antagonisten, leiten, wobei der Fokus auf entscheidenden Studien bei LVAD-Patienten und anderen seltenen kardiovaskulären Erkrankungen liegt, die eine lebenslange Antikoagulationstherapie erfordern.
Dr. Ferguson kommt von Matinas BioPharma, wo er als Chief Medical Officer tätig war. Zuvor war er Leiter der US-amerikanischen kardiovaskulären Medizinische Angelegenheiten bei Amgen und hatte verschiedene leitende Positionen bei AstraZeneca inne. Die Ernennung zielt darauf ab, die Entwicklung von tecarfarin als die erste Innovation in der vitamin-K-zielgerichteten Antikoagulation in 70 Jahren voranzutreiben.
- Appointment of highly experienced CMO with 25+ years in cardiovascular leadership
- Strategic focus on late-stage clinical development of tecarfarin
- Potential first innovation in vitamin K-targeted anticoagulation in 70 years
- None.
Insights
The appointment of Dr. James Ferguson as CMO marks a significant strategic development for Cadrenal Therapeutics' tecarfarin program. His track record in cardiovascular drug development, particularly his experience with BRILINTA at AstraZeneca and cardiovascular medical affairs leadership at Amgen, brings important expertise for navigating the complex late-stage clinical development landscape.
The focus on LVAD patients and rare cardiovascular conditions represents a smart market positioning strategy. The anticoagulation market for these specific indications faces significant challenges with traditional warfarin therapy, creating a clear opportunity for tecarfarin as the first innovation in vitamin K antagonist therapy in seven decades.
For investors, three key aspects merit attention:
- The timing of this appointment suggests Cadrenal is preparing for a critical phase in tecarfarin's development, with the pivotal trial in LVAD patients on the horizon
- Dr. Ferguson's extensive relationships with cardiovascular thought leaders could accelerate trial recruitment and potentially streamline the regulatory process
- His experience in business development indicates potential for pipeline expansion beyond tecarfarin, providing additional value creation opportunities
The transition occurs at a important juncture as the company moves toward late-stage clinical development, positioning Cadrenal to potentially address significant unmet needs in specialized anticoagulation therapy. Dr. Ferguson's expertise in both clinical development and medical affairs suggests a comprehensive approach to drug development that could enhance tecarfarin's path to market.
- James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer
- Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities
Dr. Ferguson replaces Douglas W. Losordo, MD. Cadrenal thanks Dr. Douglas Losordo for his contributions to advancing the development of our tecarfarin program.
“We welcome Dr. Ferguson to our team and are confident that he will play a critical role in driving the late-stage clinical development of tecarfarin and the prioritization of indications. Dr. Ferguson brings expertise and strong relationships with cardiovascular clinical and scientific thought leadership, which will be instrumental as we prepare for late-stage clinical development of our tecarfarin program,” said Quang X. Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc.
Dr. Ferguson joins Cadrenal after serving as Chief Medical Officer at Matinas BioPharma. Previously, Dr. Ferguson was Head of
“I’m truly honored to be joining Cadrenal at this exciting and transformative time. I look forward to advancing the late-stage clinical development of tecarfarin and bringing forward the first innovation in vitamin K-targeted anticoagulation in 70 years. This product could have a truly meaningful impact for patients in whom there continues to be major unmet medical needs with standard warfarin therapy,” said Dr. Ferguson.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing specialized therapeutics for rare cardiovascular conditions. The Company is developing tecarfarin, a vitamin K antagonist (VKA) designed to be a better and safer anticoagulant than warfarin for individuals with implanted cardiac devices. Cadrenal strives to improve outcomes and reduce major adverse events for these patients. Although warfarin is widely used off-label for several rare cardiovascular diseases, extensive clinical and real-world data have shown it to have significant serious side effects. With its innovation, Cadrenal aims to meet the unmet needs of this patient population by relieving them and their healthcare providers of some of warfarin’s greatest clinical challenges.
Cadrenal is pursuing a product in a pipeline approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted left ventricular assist devices (LVADs). In 2025, the Company plans to initiate a pivotal Phase 3 trial evaluating tecarfarin versus warfarin for LVAD patients. The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).
Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapies. For more information, visit www.cadrenal.com and connect with us on LinkedIn.
Safe Harbor
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding the contributions to be made by Dr. Ferguson including leading the late-stage clinical development of tecarfarin to include the pivotal trial in LVAD patients and other indications in rare cardiovascular conditions requiring life-long anticoagulation therapy as well as other business development opportunities to build the Company’s pipeline, as well as advancing other indications in rare cardiovascular conditions requiring chronic anticoagulation; playing a critical role in driving the late-stage clinical development of tecarfarin and the prioritization of indications; Dr. Ferguson’s expertise and strong relationships with cardiovascular clinical and scientific thought leadership being instrumental as the Company prepares for the for late-stage clinical development of our tecarfarin programs; advancing the late-stage clinical development of tecarfarin and bringing forward the first innovation in vitamin K-targeted anticoagulation in 70 years; the product having a truly meaningful impact for patients in whom there continues to be major unmet medical needs with standard warfarin therapy; the Company striving to improve outcomes and reduce major adverse events for patients; the Company aiming to meet the unmet needs of the patient population by relieving them and their healthcare providers of some of warfarin’s greatest clinical challenges; and the Company initiating in 2025 a pivotal Phase 3 trial evaluating tecarfarin versus warfarin for LVAD patients. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to derive benefits from the contributions expected to be made by Dr. Ferguson; the ability to initiate the pivotal Phase 3 clinical trial for tecarfarin in LVAD patients in 2025 and provide improved outcomes; the ability to enter into collaborations with development partners; the ability of tecarfarin to provide a safer alternative to LVAD patients and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206066131/en/
Lisa DeScenza
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com
Source: Cadrenal Therapeutics, Inc.
FAQ
What is the significance of tecarfarin development for CVKD?
Who is the new Chief Medical Officer at Cadrenal Therapeutics (CVKD)?
What are the target patient groups for CVKD's tecarfarin?
What is Dr. Ferguson's role in CVKD's tecarfarin development?
